Symbiotic Mind & Body Presentation

1. A New Understanding of What Causes
Uncontrolled Cravings, Low Energy,
Stress, Fat Storage, and Un-Happiness
Empowering a Balanced
Mind and Body

2.  Conventional Wisdum:
 You are Fat Because You Eat Too
Much and You Don’t Exercise
Enough
 If that was true then Everyone who
ate less and exercised more would be
thinner than Everyone who didn’t
 And we KNOW that is not the case

3.  The Key issue is NOT that people eat
more and exercise less
 But, WHY do people Eat More and
Exercise Less?
 The conventional perspective is forced to
conclude that they are Lazy Gluttons
 BUT, the real answer resides in how
your genes respond to your lifestyle
activities….
 Your Body Has…

4. 1. To SURVIVE,… AND
2. To Achieve PLEASURABLE and REWARDING
experiences, and avoid painful & stressful ones
 These are the GENETIC PRIME DIRECTIVES that
drive ALL behaviors
 Any strategy to achieve optimal health MUST
satisfy BOTH mandates
 Deprivation- or abstinence-dependent tactics
alone cause survival/reward panic & Resistance
 “White Knuckle Abstinence”

5.  Deprivation
 Reducing calorie (and nutrient) intake/absorption
using sugar & fat blockers, calorie restricted diets,
appetite suppressants, fiber/water fill-you-up pre-
meal bulking agents, etc. ~ad nauseum
 Stimulation
 Fat burners & Central nervous system stimulants –
caffeine, synephrine, salicylic acid, gotu kola, etc…
 Elimination
 Herbal diuretics, colon cleansers, laxatives, etc…
 Excessive Exercise
 All Cause a Defensive Survival Reaction

6.  Lower the BMR – Energy Retardation and
Conservation
 Lower the muscle cells ability to produce
energy
 Increased fatigue
 Increase Energy Storage
 Fat is Survival Insurance
 Increase Cravings & Energy Consumption
 This is Metabolic Retardation – The Real
Energy Crisis

7.  So, are the Conventional strategies that focus
Entirely on ‘Reducing Heaviness’ by variations
of the genetically defiant tactics of deprivation,
stimulation, and elimination wrong?
 YES!!!...SO…
 What is a lead cause of the desire to overeat?
 What is a lead cause of low energy & fatigue
 And the low motivation to be more active
 It’s not an excess Fat Crisis; It’s an Energy Crisis
 What has to happen BEFORE the body will let
go of fat, i.e. stored energy ala ‘Survival
Insurance’

8.  Lifestyle Choices
 Taking in not enough of the good and too
much of the bad
 i.e. Nutritional Deficiencies + Toxic and
Overburdening Excesses ill health
 ‘Dis’Stress
 Which adds to ‘too much of the bad’ factor
 Genetic Predispositions
 We can’t change our genes
 BUT, we CAN improve (Optimize) gene
expression
 Epigenetics and Nutrigenomics

9.  FACT: Any strategies to improve vitality,
energy, stress relief, body composition,
and overall health must FIRST promote a
Metabolic Correction in a genetically
allowable ‘Body Friendly’ manner.
 Reducing heaviness is not the priority
 MUST Fix the ‘Deficient Energy’ Crisis

10. How Gene Variants (Polymorphisms)
Retard Energy Production,
Increase Cravings & the Risk of
Excessive
Reward Seeking Behaviors

11. The Brain
Reward
Cascade

12. Gene
Targets in
the Brain
Reward
Cascade

13. Nutrients
at Specific
Dosages
That
Improve
Gene
Expression
& Optimize
“Reward”

14. Pleasure
Pathway
Immune Stress
Pathway
Pathway
CRAVING
RISK
Energy
Neuro-
and
endocrine
Pathway
Metabolic
Pathway

15.  The brain is hard wired to feel good. Dopamine is the
„feel good, stress relief and happy‟ neurotransmitter!
 Dopamine is the „Payoff‟ of the “Brain Reward Cascade”
but exerts an interactive direct and indirect influence on
other important neurotransmitters, hormones, and
metabolic molecules like:
Serotonin Enkephalin/Endorphin Norepinephrine
GABA
 Cholecystokinin Insulin Leptin Ghrelin Substance
P ATP…etc.
 Problems that can occur with dopamine include:
 Dopamine deficiency Reduced dopamine sensitivity
Reduced amount of dopamine receptors Dopamine
Resistance “Reward Deficiency Syndrome” (RDS), etc.

16.  Two Factors are key to Dopamine
Sensitivity and Function
 Synthesis
 Receptivity
 Dopamine has 5 types of Receptors
 D1-D5
 Dopamine D2 Receptors are Most
Important for Cravings, Reward, Stress
Relief, Energy, and Feelings of Happiness
 There are at least Two Forms of D2
Receptors
 A1
 A2
 But…they come in pairs, so there are three
variations – A1/A1; A1/A2; A2/A2

17. A2 Gene = Normal # of DRD2 Receptors

18. A1 Gene = >1/3 Less D2 Receptors
DA ‘R e s i s t a n c e’

19. (Over 100,000,000 people)

20.  50% of African Americans carry
the DRD2 A1 gene
 58% of Hispanics carry the DRD2
A1 gene
 72% of Asians carry the DRD2 A1
gene
 85% of Native Americans carry
the DRD2 A1 gene
Barr & Kidd, Bio Psych 1993

21.  Adequate dopamine (DA) function improves
energy and creates feelings of
pleasure, satisfaction, satiety, motivation, happi
ness, and more.
 Dopamine Resistance causes an increased need
for a pleasure-satisfying “dopamine fix”
 The “Dopamine Fix” is pursued by eating sugary
& fatty foods; over-
eating, drinking, drugs, gambling, sex, internet
gaming, thrill seeking behaviors, etc. (ALL
excessive ‘Reward Seeking Behaviors”)
 This is called “Reward Deficiency Syndrome”
(RDS) Blum et al. JRSM, 1996

22.  Dopamine Resistance =
 Hypodopaminergic Function
 Low number of dopamine receptors
 Reduced dopamine release
 Low dopamine responsivity
 Impaired dopamine function
 Increased (excessive) dopamine stimulating
behaviors
 Substitution/Transfer Addiction
 Chemical
Substances, Sugar/Food, Risk/Excess, Consumpti
on/Compensation Behaviors, etc.

25.  Inability to cope with  Blunted reward
stress response to pleasurable
 Reduction of energy experiences
expenditure  Intensified bingeing
 Lower BMR (Energy behavior
Conservation) and
Fatigue  Addictive behaviors
 Increased carbohydrate  Thrill-seeking behaviors
& fat cravings  Impulsive behaviors
 Increased food intake  Compulsive behaviors
 Energy consumption  Personality disorders
 Increased blood  Poor executive function
pressure  Reduced global
 Increased % body fat cognition
 Higher Body Mass Index

26. Addictive Impulsive Compulsive Personality
Behaviors Behaviors Behaviors Disorders
severe attention-deficit aberrant sexual conduct
alcoholism disorder behavior disorder
hyperactivity
polysubstance tics & Tourette Internet antisocial
abuse Syndrome gaming personality
smoking autism pathological aggressive
gambling behavior
Over Obsessive/
Compulsive
Eating - Disorder
obesity Blum et al. Am Sci, 1996

27. Research On Social  Genetic Research
Networks Blum’s group found
Research at UC San that in a family with
Diego found that the very serious RDS
A1 allele is common behavior, the A1 allele
among friends up to was present in 100% of
3 degrees of married males and
separation females down five
generations
Fowler et al. PNAS,2011 Blum et al Int J Env Res Pub Health,2011.

28. Stress lowers brain endorphins
and increases craving behavior
Blum et al, JPD, 2000

29. A Nutrigenomic Solution

30. ‘Symbiotic MB™’ contains
Endorphamine®, the KB220Z
Neuroadaptogen shown to
naturally activate the dopamine
Reward Pathway in the brain and
‘normalize’ Dopamine Function

31. Blum et al. Gene Ther Mol Biol 2008

32. Obesity is an Epigenetic
induced RDS condition that
positively responds to
nutritional support of the brain
reward cascade and dopamine
agonist actions of the KB220Z
neuroadaptogen complex.

33. PERCENT PREVALENCE DRD2 A1 POSITIVE CORRELATION OF
ALLELE & BODY FAT AS
MEASURED BY DEXA LEPTIN LEVELS AND FAT MASS
Leptin in ng/mL
Fat Mass in Kg
Chen et al. Food & Function, 2011 Thomas et al. Metabolism, 2000

34.  Weight loss, uncontrollable carbohydrate bingeing and
relapse rates were evaluated in 27 outpatients for 90 days, all
of whom were attending a supervised reduced calorie diet-
controlled treatment program. The patients were assigned to
two matched treatment groups:
 Those receiving KB220 (N= 16) and,
 Those not receiving KB220 (N=11).
 After 90 days, the KB220 group lost an average of 27
pounds. The Non-KB220 control group lost only 10.2
pounds.
 Only 3 subjects (out of 16) in the KB220 group relapsed in
contrast to 9 subjects (out of 11) in the Non-KB220 control
group.
 Over the 90 day period, the KB220 group was easily able to
comply with the mandated prohibition from carbohydrate
bingeing compared to the subjects in the Control (no
KB220).
Blum et al., Current Therapeutic Research 1990.

35. Reduces Weight (90 Day Study)
Blum et al., Current Therapeutic Research 1990.

36. Prevents Relapse (90 Day Study)
Blum et al., Current Therapeutic Research.

37.  The effects of LG839 intake in 21 individuals were
evaluated in an open label study.
 Pre- and post study analysis revealed a significant
difference between starting BMI and the BMI after an
average of only 41 days of LG839 intake.
 The pre-BMI was 31.2 (weight/Ht2) compared to the
post BMI of 30.4 (weight/Ht2) with a significance value
of P <0.034.
 Similarly the average pre–weight in pounds was 183.52
compared to the post weight of 179 pounds with a
significance value of P < 0.047 (average weight loss of
4.52 lbs or 2.5% of starting weight).
 This research found, and confirmed, trends of reduced
late night snacking and carbohydrate craving, reduction
of stress, and reduction of waist circumference.
Blum et al. 2008 Gene Therapy & Mol. Biol. 12: 371-382

38.  A 2-year study was conducted to evaluate the efficacy
of Optifast® (a meal replacement drink) in a ‘fasting’
program.
 Following its termination, 247 of the subjects of that
original study who had difficulty attaining and/or
maintaining their desired weight constituted the
experimental group in a second two-year study (84.2%
were female; 73% of which were morbidly obese).
 The experimental group participated in a very low
calorie fasting program and was divided into 2 sub-
groups.
 one taking Centrum (N=117) and,
 the other group, expressing the highest complaint of
difficulty in weight loss (the hardest cases in the 4 year
study!), took KB220 plus Centrum (N=130).

39.  After the second 2-year term, compared to the Centrum
control group, the Centrum + KB220 (patented formula)
group achieved the following results
 a twofold decrease in percent overweight for both males and
females;
 a 70% decrease in food cravings for females and a 63% decrease
in males;
 a 60% decrease in binge eating for females and a 41% decrease
for males.
 Most importantly, similar to the KB220 - 1 study, at the end
of the 2 year study, the KB220 - 2 study group only gained
back 14.7% of the weight lost during the fasting program.
The Centrum control group regained 41.7% of the lost
weight(1).
 Statistical analysis also revealed that morbid obesity and
binge eating scores were significant predictors of how
beneficial the KB220 treatment would be at preventing
weight gain after 2 years.
 The more you need it, the better it works!
Blum et al. Current Therapeutic Res. 1997

40. # of Total Lbs Regained
Study Duratio Subject Weight lost/wk Weight
n s Lost
KB220-1 12.86 16 27 lbs 2.1 lbs 3 people
wk
(90 days)
Non 12.86 11 10.2 lbs 1.26 lbs 9 people
KB220 wk
(90 days)
LG839 5.86 wk 21 4.52 lbs 0.77 lbs
OL (41 days)
KB220+ 2 years 130 2Xs Post Fast
Centrum 14.7%
better
Centrum 2 years 117 X Post Fast
Only 41.7%

41.  Research tested whether abnormalities in
food reward predict weight gain over a 1-
year follow-up (Study 1)
 Carriers of the A1 allele experienced a
‘blunted response’ to palatable food and
increased consumption
 A1 allele interacted with responsivity to
predict increases in BMI from baseline to 1-
year follow-up
Stice et al. Neuroscience, 2011

42. KB220Z Neuroadaptogen Benefits
Other Reward Deficiency
Syndrome Behaviors

43. Brain Map of RDS Victims
Impairment of Reward Sensitivity
Braverman & Blum, Clin EEG, 1996

44. Placebo (n=5) Brain Reward Solution (n=5)

45. Normal Reward Variant Reward
Circuitry in the Circuitry in the
Brain Brain
(Non-Addict (Addict
Or Non-Gene) Or Gene)
Shows a Healthy Shows
Number of Reduced
Receptor Sites Receptor Sites

46.  Pre-KB220  Post-KB220

47. IV KB220 qEEG Study
After Before
Subject 1.1: Post Amino Acid qEEG (Fig. 2)
Post qEEG analyses shows decreased frontal theta (4-8hz) and decreased frontal
beta (12-15hz) indicating improved functioning immediately post amino acid
intravenous treatment. Miller et al., Post Graduate Medicine 2010

48. In a triple blind placebo controlled qEEG
study, KB220Z significantly increased
alpha with concomitant increases in low
beta bands compared to placebo
resulting in a normalization of brain
function in protracted abstinent psycho
stimulant addicts
Blum et al., Post Graduate Medicine 2010

49. KB220Z vs Placebo in Psychostimulant
Addicts
70
FFT Absolute Power (microvolts)
60
50
40
30 Placebo
20 KB220Z
10
0
Alpha(12-15Hz) Beta1(15-18Hz)
qEEG Bands
Blum et al Post Grad Med, 2010

50. CRAVING RELAPSE
 Caudate  Pre-frontal cortex
 N. Accumbens  Cingulate Gyrus
 Putamen
fMRI qEEG
 Increases Alpha bands
 Activates Dopamine
Pathway  Increases Low beta bands

51. One year outpatient Recovery Program
for Both Federal and Municipal Court
Systems in the Bio-Clarity
Rehabilitation Clinic in Las Vegas
using the KB220 Complex
Alcoholism Relapse Rate was Only 7%
Chen TJH, et al. Adv Therapy 2007

52. Reduces Craving Behavior
Chen TJH, et al. Adv Therapy 2007

53. „Building Up to Relapse‟
(“Building Up To Relapse”)
Brown et al JPD, 1989

54. Brown et al JPD, 1989

55. Blum et al. JTAS, 2007

56.  A preliminary study of 106 eating disordered females was
conducted at a medically supervised outpatient addiction
treatment program (Recovery Systems, Inc.), utilizing the
patented Symbiotic MB (SMB) formula for this application.
 In follow-up interviews, six randomly selected former eating
disordered female clients (three of which were also
chemically dependent) were contacted nine months to three
years post-treatment to evaluate efficacy of the BRS formula.
 Follow-up confirmed significant initial benefits in elevated
mood and freedom from compulsive eating behavior and
ideation to eat in 100% of the subjects.
 In the other 100 patients, 98% experienced significant
improvement in both mood and reduced sugar craving
behavior.
 The preliminary work has been completed and published.
However, the research is still in progress with the
commencement of a ten–year extensive follow–up study.
[Ross J. Molecular Psychiatry, 2000 S8]

57.  Taking the patented Endorphamine®
formula in Symbiotic MBTM, >80% of
recovering alcoholics were able to abstain
from taking a drink for an average of 11
months; the duration of the study period.
(also reducing ‘white knuckle sobriety’ and
promoting a greater sense of happiness)
 Nutritionally supports over an 80%
recovery rate and greater ‘happiness’.
Brown et al. J Psychoactive Drugs. 1990
57

58. The patented Endorphamine® formula
in the Symbiotic MBTM significantly
reduced relapse rates and enhanced
recovery in DUI outpatient offenders
over a 10-week period. Follow-up after
10 months revealed an average 83%
continued overall recovery rate.
Brown et al. Psychoactive Drugs. 1990.

59. A significant increase in Cognitive
and Attention Processing Speed (P300
component) of the ‘Event Related
Potentials’ and ‘Contingent
Continuous Performance Task’ was
seen after taking the patented KB220Z
complex in the Symbiotic MBTM
De France et al. Clin Electro Encephalograph. 1997.

60. KB220Z Increases Attention & Concentration
De France et al Clin EEG, 1997

61.  The Symbiotic MB ™ positively influences gene
expressions that drive the brain’s control of every
bodily function (especially in the dopamine
receptor genes) and its reaction to
environmental/lifestyle forces.
 Symbiotic MB™ results in:
 Reduced Cravings
 Greater Self-Control
 No More Feelings of Helplessness
 Increased Energy, Vitality, and Sense of Wellness
 Reduced Stress and Anxiety
 Greater Focus, Concentration, Cognition
 Improved Executive Function
 Elevated Mood and Greater Sense of Happiness